ASIC
To date, Alzheimer’s disease is known to be a continuum from a pre-clinical, ”silent” phase, to dementia, characterized by the early presence of various biological markers of the ongoing disease processes. Individuals at increased risk of sporadic Alzheimer’s disease, such as carriers of the APOE4 gene, offer a unique opportunity to study these early and subtle brain changes. The ASIC-E4 study utilizes PET imaging, magnetic resonance imaging and fluid biomarker measurements to investigate the interplay of early pathological markers in cognitively unimpaired APOE4 carriers.
Funding: Emil Aaltosen säätiö, Orionin tutkimussäätiö, paulon säätiö, valtion tutkimusrahoitus, Suomen Akatemia (#341059)
Collaborators: Auria biopankki, Göteborgin yliopisto, Åbo Akademi
Main publications:
Snellman A, Ekblad LL, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Pietilä E, Koivumäki M, Helin S, Karrasch M, Zetterberg H, Blennow K, Rinne JO. Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer’s disease. Neurobiol Dis. 2023 Jul;183:106175.
Ekblad LL, Tuisku J, Koivumäki M, Helin S, Rinne JO, Snellman A. Insulin resistance and body mass index are associated with TSPO PET in cognitively unimpaired elderly. J Cereb Blood Flow Metab. 2023 Apr 27:271678X231172519. Online ahead of print.
Snellman A, Ekblad LL, Tuisku J, Koivumäki M, Ashton NJ, Lantero-Rodriguez J, Karikari TK, Helin S, Bucci M, Löyttyniemi E, Parkkola R, Karrasch M, Schöll M, Zetterberg H, Blennow K, Rinne JO. APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly. Alzheimers Res Ther. 2023 Apr 4;15(1):71.
Snellman A, Ekblad LL, Koivumäki M, Lindgrén N, Tuisku J, Perälä M, Kallio L, Lehtonen R, Saunavaara V, Saunavaara J, Oikonen V, Aarnio R, Löyttyniemi E, Parkkola R, Karrasch M, Zetterberg H, Blennow K, Rinne JO. ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and